Skip to content

HIIT vs HRV-based Training for Rehabilitation After Stroke

High Intensity Interval Training (HIIT) vs Heart Rate Variability (HRV) Training for Cardiac and Functional Rehabilitation After Stroke

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05612776
Enrollment
60
Registered
2022-11-10
Start date
2022-12-01
Completion date
2023-12-01
Last updated
2022-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease, Ischemic Heart Disease, Ischemic Stroke, Stroke, Stroke, Ischemic

Keywords

Heart Rate Variability, HIIT, cardiac rehabilitation, safety, adherence, VO2peak

Brief summary

Consequences of stroke are manyfold but all of them are important factors on the long-term outcomes of rehabilitation, becoming an important health problem with requires health strategies with advanced age. High intensity interval training (HIIT) is an efficient training protocol used in cardiac rehabilitation programs, but owing to the inter-individual variability in physiological responses to training associated to cardiovascular diseases, the exercise dose received by each patient should be closely controlled and individualized to ensure the safety and efficiency of the exercise program. The heart rate variability (HRV) is actually being used for this purpose, as it is closely linked to de parasympathetic nervous system activation. In this way, higher scores in HRV are associated with a good cardiovascular adaptation. The objective of this protocol is to determine the effect of HIIT compared with HRV-guided training on cardiorespiratory fitness, heart rate variability, functional parameters, body composition, quality of life, inflammatory markers, cognitive function, and feasibility, safety and adherence in patients after stroke undertaking an 8-week cardiac rehabilitation program. This will be a cluster-randomized controlled protocol in which patients after stroke will be assigned to an HRV-based training group (HRV-G) or a HIIT-based training group (HIIT-G). HIIT-G will train according to a predefined training program. HRV-G training will depend on the patients' daily HRV. The peak oxygen uptake (VO2peak), endothelial and work parameters, the heart rate variability, the functional parameters, the relative weight and body fat distribution, the quality of life, the inflammatory markers, the cognitive function, and the exercise adherence, feasibility and safety will be considered as the outcomes. It is expected that this HRV-guided training protocol will improve functional performance in the patients after stroke, being more safe, feasible and generating more adherence than HIIT, providing a better strategy to optimize the cardiac rehabilitation interventions.

Interventions

OTHERHIIT

HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.

OTHERHRV

The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.

Sponsors

CEINSA, University of Almeria
CollaboratorUNKNOWN
Universidad de Almeria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* left ejection fraction higher than 30% after stroke * aged between 18 and 80 years old

Exclusion criteria

* presence of absolute or relative contraindications for accomplishing the treadmill test, indicated by the Spanish Society of Cardiology * being treated for other diseases, or regularly taking a drug(s) that has a direct or indirect effect on the nervous system (e.g., anxiolytics, antidepressants or neuroleptics) * absence of medication to control the cardiovascular disease or its modification during the intervention * people who are participating or have participated in the previous three months in other similar exercise programs * not performing at least 80% of the workouts during the intervention

Design outcomes

Primary

MeasureTime frameDescription
Peak oxygen uptake (VO2peak) changesbaseline and week 8According to the Spanish Society of Cardiology, the modified Bruce procotol will be used as a treadmill test, as it is indicated for people considered to be at high risk and the elderly.

Secondary

MeasureTime frameDescription
Functional performanceBaseline and week 8To measure functional capacity, the Senior Fitness Test battery will be used such as the Six Minutes Walk Test Or Timed Up and Go Tests, as it has been used in previous studies in which a program based on high-intensity training has been implemented with elderly people.
Cognitive function, spatial memory recognition testbaseline and week 8the spatial memory recognition test (ASMRT), a simple virtual reality based task for specific population like older adults and with proved sensitivity to gender differences
Body mass index (BMI)Baseline and week 8Height will be measured using a measuring rod (Seca 213), and the body mass index (BMI) will be calculated according to the formula: BMI = kg/m2.
Quality of life MacNewBaseline and week 8the MacNew QLMI post-myocardial infarction quality of life questionnaire will be administered. Consists of a 27-question questionnaire answered on a scale of 1 to 7, where 1 means always and 7 means never.
Number of participants with abnormal laboratory test resultsbaseline and week 8The blood analysis will include the lipid profile, the detection and quantification of plasma insuline and its' resistance.
Waist-to-hip ratioBaseline and week 8As body fat distribution can vary substantially, and having into account that abdominal adiposity has been associated with coronary heart disease, Waist-to-hip ratio will be measured according to International Society for the Advancement of Kinanthropometry Standards.
Heart rate variabilityevery day before starting the interventionHRV is proposed to be measured at rest, just before the training session, in a laying position and over a 60 second period. Smartphone application known as HRV4Training will be used.
Cognitive function, virtual version of the Walking Corsi testbaseline and week 8the virtual version of the Walking Corsi test (VR\_WalCT) will be used to measure topographical memory, as proved its' equivalency regarding the real environment one
Cognitive function, Trail Making Testbaseline and week 8the Trail Making Test (TMT) will be used to detect neurological disease and neuropsychological impairment through the cognitive domains of processing speed, sequencing, mental flexibility and visual-motor skills.
Exercise Adherenceup to 8 weeksAdherence will be assessed by the number of sessions completed by the participants. At least, the 80% of the sessions should be achieved to consider a successful adherence.
Feasibility studyup to 8 weeksFeasibility study will be considered as the compliance to the exercise protocol, and will be registered as the percentage of participants that finished every training session.
Safety studyup to 8 weeksSafety study will be measured as the numbers of adverse events occurred during the training sessions. They will be registered as mild, moderate and severe. Moreover, their relation to the exercise session will also be taken into account.
Waist-to-height ratioBaseline and week 8In the same way, waist-to-height ratio will be also measured as a recent systematic reviews with meta-analysis have proposed it as a better predictor of cardiovascular risk factors.

Countries

Spain

Contacts

Primary ContactMaría Carrasco, PhD
carrasco@ual.es+34950214773

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026